Stephen Chia
Advertisement
Articles by Stephen Chia
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
Advertisement
Latest Updated Articles
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE TrialPublished: June 23rd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Issues CRL for Dasatinib in CML/ALL
2
Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma
3
Oral SERD Regimen May Prolong Efficacy in Second-Line Breast Cancer Care
4
Why is Radiotherapy Not More Accessible as a Cancer Treatment?
5
